ScoreComparison
Company
Score
Quality
Valuation
Financial
Technical
Why is ANI Pharmaceuticals, Inc. ?
1
The company is Net-Debt Free
2
Healthy long term growth as Net Sales has grown by an annual rate of 33.48%
3
With a growth in Operating Profit of 11.97%, the company declared Outstanding results in Mar 26
- The company has declared positive results for the last 4 consecutive quarters
- OPERATING CASH FLOW(Y) Highest at USD 208.62 MM
- NET SALES(9M) At USD 712.34 MM has Grown at 32.89%
- ROCE(HY) Highest at 17.27%
4
With ROCE of 9.39%, it has a fair valuation with a 2.27 Enterprise value to Capital Employed
- The stock is trading at a discount compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of 13.39%, its profits have risen by 572.8% ; the PEG ratio of the company is 0.1
5
High Institutional Holdings at 100%
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
Real-Time Research ReportHow much should you buy?
- Overall Portfolio exposure to ANI Pharmaceuticals, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is ANI Pharmaceuticals, Inc. for you?
Medium Risk, Medium Return
Absolute
Risk Adjusted
Volatility
ANI Pharmaceuticals, Inc.
13.39%
0.66
30.93%
S&P 500
22.36%
1.70
13.18%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
33.48%
EBIT Growth (5y)
48.48%
EBIT to Interest (avg)
-0.55
Debt to EBITDA (avg)
36.46
Net Debt to Equity (avg)
1.18
Sales to Capital Employed (avg)
0.66
Tax Ratio
23.63%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
2.20%
ROE (avg)
1.25%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
37
Industry P/E
Price to Book Value
3.03
EV to EBIT
24.17
EV to EBITDA
11.37
EV to Capital Employed
2.27
EV to Sales
2.22
PEG Ratio
0.07
Dividend Yield
NA
ROCE (Latest)
9.39%
ROE (Latest)
8.30%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Sideways
Bullish
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Bullish
Dow Theory
No Trend
Mildly Bearish
OBV
No Trend
Mildly Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend33What is working for the Company
OPERATING CASH FLOW(Y)
Highest at USD 208.62 MM
NET SALES(9M)
At USD 712.34 MM has Grown at 32.89%
ROCE(HY)
Highest at 17.27%
OPERATING PROFIT(Q)
Highest at USD 59.62 MM
PRE-TAX PROFIT(Q)
Highest at USD 34.29 MM
NET PROFIT(Q)
Highest at USD 23.08 MM
RAW MATERIAL COST(Y)
Fallen by -0.87% (YoY
CASH AND EQV(HY)
Highest at USD 620.85 MM
INVENTORY TURNOVER RATIO(HY)
Highest at 3.21 times
DEBTORS TURNOVER RATIO(HY)
Highest at 3.88 times
OPERATING PROFIT MARGIN(Q)
Highest at 25.11 %
EPS(Q)
Highest at USD 1.28
0What is not working for the Company
NO KEY NEGATIVE TRIGGERS
Here's what is working for ANI Pharmaceuticals, Inc.
Operating Profit
Highest at USD 59.62 MM and Grown
In each period in the last five periodsMOJO Watch
Near term Operating Profit trend is quite positive
Operating Profit (USD MM)
Pre-Tax Profit
Highest at USD 34.29 MM and Grown
In each period in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is very positive
Pre-Tax Profit (USD MM)
Pre-Tax Profit
At USD 34.29 MM has Grown at 118.65%
over average net sales of the previous four periods of USD 15.68 MMMOJO Watch
Near term Pre-Tax Profit trend is very positive
Pre-Tax Profit (USD MM)
Net Profit
Highest at USD 23.08 MM and Grown
In each period in the last five periodsMOJO Watch
Near term Net Profit trend is very positive
Net Profit (USD MM)
Net Profit
At USD 23.08 MM has Grown at 105.73%
over average net sales of the previous four periods of USD 11.22 MMMOJO Watch
Near term Net Profit trend is very positive
Net Profit (USD MM)
Net Sales
At USD 712.34 MM has Grown at 32.89%
Year on Year (YoY)MOJO Watch
Near term sales trend is positive
Net Sales (USD MM)
Operating Cash Flow
Highest at USD 208.62 MM
in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (USD MM)
Operating Profit Margin
Highest at 25.11 %
in the last five periodsMOJO Watch
Company's profit margin has improved
Operating Profit to Sales
EPS
Highest at USD 1.28
in the last five periodsMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (USD)
Cash and Eqv
Highest at USD 620.85 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is improving
Cash and Cash Equivalents
Inventory Turnover Ratio
Highest at 3.21 times
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its inventory faster
Inventory Turnover Ratio
Debtors Turnover Ratio
Highest at 3.88 times
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its Debtors faster
Debtors Turnover Ratio
Raw Material Cost
Fallen by -0.87% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
